TriNet Announces Quarterly Dividend
About TriNet
TriNet provides comprehensive HR solutions, technology, expertise, and access to world-class benefits that enable small and medium-sized businesses to attract and develop top-tier talent. Rooted in more than 30 years of supporting entrepreneurs and adapting to the ever-changing modern workplace, TriNet empowers SMBs to focus on what matters most—growing their business and enabling their people. For more information, visit TriNet.com or follow us on Facebook, LinkedIn and Instagram.
Investors:
Media:
Alex Bauer
Renee Brotherton/Josh Gross
TriNet
TriNet
Alex.Bauer@TriNet.com
Renee.Brotherton@TriNet.comJosh.Gross@TriNet.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/trinet-announces-quarterly-dividend-302480673.html
SOURCE TriNet Group, Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Moon Surgical Launches Maestro™ Platform at Lee Health
PARIS and SAN FRANCISCO, July 15, 2025 /PRNewswire/ -- Moon Surgical, the leader in Physical AI for the operating room, today announced the successful launch of its Maestro™ Platform at Lee Health's Gulf Coast Medical Center in Fort Meyers, Florida, marking another milestone in the platform's growing adoption across the United States. Lee Health has already completed over 100 procedures using Maestro, including bariatric and general surgeries. Notably, the hospital reported: Zero adverse events No increase in operative time or length of stay, even in the initial cases Operational efficiencies which enable the reduction of one surgical technologist or advanced provider per case without compromising care In just the first 25 bariatric cases, Maestro helped Lee Health save the equivalent of 8.3 full working days of surgical tech time, demonstrating its impact on staffing efficiency and resource optimization. QUOTE: Juan Ibarra, M.D - Robotic Surgery Program Manager, Lee Heath: "We're proud to be among the early U.S. institutions to adopt the Maestro Platform. We've completed over 100 procedures, each one delivering excellent clinical and operational outcomes. For surgeons who prefer traditional laparoscopy, Maestro offers a smart and reliable assistant without changing their preferred surgical approach. We are proud at Lee Health to be setting the pace with technology that improves efficiency, maintains safety, and supports our teams." "The program launch and partnership with Lee Health is a great example of how Maestro is defining a new category of MIS." said Anne Osdoit, Moon Surgical CEO. "Maestro has quickly delivered consistent and scalable positive impact for surgeons, their teams, the hospital system and its patients." The launch at Lee Health comes on the heels of a recent announcement on the rapidly broadening usage of the Maestro™ System, which has now supported over 1,600 procedures worldwide, including 1,400 in the past year alone, across 60 different types of minimally invasive surgeries. Maestro's growing adoption highlights its adaptability across specialties and its value in high-volume outpatient care. Moon Surgical continues to redefine the operating room with Maestro, a surgical technology platform powered by Physical AI. Designed to enhance human performance, Maestro supports surgical teams with adaptability, control, and efficient integration into existing workflows. About Moon Surgical Moon Surgical is transforming the operating room with Physical AI, seamlessly integrating intelligence and robotics to elevate the capabilities of surgical teams. The Maestro System represents a new category of minimally invasive surgery—expanding the scale at which robotics are delivered into the operating rooms. Instinctive, collaborative, and cost-effective, Maestro empowers teams to deliver exceptional care with greater adaptability and control. Moon Surgical. Inspiring and Innovating the Art of Surgery. Moon Surgical® and Maestro® are registered trademarks of Moon Surgical, SAS View original content to download multimedia: SOURCE Moon Surgical
Yahoo
5 minutes ago
- Yahoo
Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")
NEW YORK, July 10, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company's novel secreted-Klotho (s-KL) promoter, gene and delivery system (KLTO-202, or for the treatment of ALS. The FDA grants Orphan Drug Designation to drugs and biologics that are intended for safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. The Orphan Drug Designation provides certain incentives, such as tax credits, toward the cost of human clinical trials and a waiver for the payment of the GDUFA User Fee for market applications. Additionally, Orphan Drug Designation of the product provides the developers seven years of US market exclusivity and independent from the Company's intellectual property protection. "Receiving the Orphan Drug Designation for for the early treatment of ALS underscores the importance of bringing new treatment options to patients suffering from this rare, universally fatal disease" said Dr. Joseph Sinkule, Klotho's Chief Executive Officer. "My cousin Karen died from this horrific disease. We aim to deliver the first gene replacement therapy addressing the neurologic insult resulting in motor neuron damage and the potential neurologic protection induced by providing therapeutic blood, brain, and muscle concentrations of the s-KL protein. After the FDA's review of the data leading to the Orphan Drug Designation, we believe this ODD designation provides strong validation of our science and our approach to treat this disease" concludes Dr. Sinkule. ALS is sometimes referred to as Lou Gehrig's disease. Lou Gehrig, who played for the New York Yankees for 17 years in the 1920s and 1930s, stunned players and fans by retiring from baseball at the age of 36 after being diagnosed with ALS. Prior to this diagnosis, Gehrig played in a record-breaking 2,130 consecutive games, was referred to as the "Iron Horse," and was considered one of the greatest baseball players of all time. Less than two years later, at the age of 37, Gehrig died of complications from ALS. ALS is also referred to as Motor Neuron Disease in the UK and elsewhere. ALS is considered a rare disease and affects fewer than 200,000 people in the US, with around 5,000 new cases diagnosed each year. Klotho Neurosciences will have completed "proof of concept" studies in two animal models of human ALS and the Company is currently initiating manufacturing of the ALS-targeted product candidate, followed by meetings with the U.S. FDA and EMA in Europe to concur with the development path going forward. KLTO-202, the company's lead product candidate targeting motor neuron diseases and muscular dystrophies, is composed of a muscle-specific promoter called "desmin," driving the expression of the s-KL gene transcript and s-KL protein, with targeted delivery of the gene therapy to the neuromuscular junction - the interface between the spinal cord and the muscles. At this time, KLTO-202 is not approved for human use by any regulatory authority. About Klotho Neurosciences, Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The Company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. For more information, please visit the company's website at Investor Contact and Corporate Communications: - Jeffrey LeBlanc, CFOir@ Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC's website, All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. View original content to download multimedia: SOURCE Klotho Neurosciences, Inc.
Yahoo
18 minutes ago
- Yahoo
LAS VEGAS SANDS BREAKS GROUND ON NEW ULTRA-LUXURY DEVELOPMENT IN SINGAPORE
Officiated by Singapore's Prime Minister and Minister for Finance Lawrence Wong, together with Las Vegas Sands co-founder Dr Miriam Adelson, the groundbreaking ceremony marks a milestone moment for the upcoming US$8 billion tourism gamechanger. SINGAPORE, July 15, 2025 /PRNewswire/ -- Las Vegas Sands (NYSE: LVS) marked a momentous milestone on Tuesday evening with the groundbreaking of its new US$8 billion ultra-luxurious resort and entertainment destination in Singapore, expanding its regional footprint and strengthening its commitment to the Republic's future. Experience the full interactive Multichannel News Release here: The occasion was officiated by Singapore's Prime Minister and Minister for Finance Lawrence Wong; Minister for Sustainability and the Environment and Minister-in-charge of Trade Relations Grace Fu; and Las Vegas Sands co-founder Dr Miriam Adelson, Chairman and Chief Executive Officer Robert Goldstein, and President and Chief Operating Officer Patrick Dumont. Robert Goldstein, Chairman and Chief Executive Officer of Las Vegas Sands, said: "With its opening in 2010, our founder Sheldon G. Adelson embarked on a journey in Singapore with Marina Bay Sands and the people of Singapore that promised to change the face of tourism in the region. Fifteen years later, we have delivered on these ambitions and more. Marina Bay Sands is the world's most successful integrated resort in history, and the gold standard in the industry. It has been truly incredible to witness Mr Adelson's vision come to life, and we are proud to carry his legacy forward with today's groundbreaking ceremony for our new development here. We have every intention of delivering a product that will be the envy of the hospitality industry and ushers in a new era of luxury tourism in Singapore." When completed, the new development is set to redefine industry standards further and push boundaries in the realms of luxury tourism, hospitality and entertainment, curating the finest and most exclusive suite of experiences for travellers. The pioneering project will feature a soaring 570-suite luxury hotel tower capped with signature rooftop and dining experiences, luxury retail boutiques, gaming, holistic spa and wellness amenities, and approximately 200,000 square feet of premium meeting space. A purpose-built 15,000-seat arena situated against the stunning backdrop of Marina Bay aims to enhance the live entertainment scene in Asia. Proving to be another extraordinary feat of engineering, the new property is being designed by the acclaimed Safdie Architects, led by Moshe Safdie—the visionary firm behind Marina Bay Sands' world-renowned design. A World Beyond Rotated at a 45-degree angle to frame panoramic views of both the Marina Bay and the Singapore Strait, the 55-storey hotel tower rises with its twin wings curving outward as they ascend toward the sky. Taking inspiration from the island's lush urban greenery, the development will see biophilic designs being integrated throughout the building along with a significant proportion of green amenities. The crowning achievement of the hotel tower is the revolutionary 76,000-square-foot Skyloop — a breathtaking haven that intuitively combines both elevated public and private spaces. As a counterpart to the iconic Sands SkyPark at Marina Bay Sands, the Skyloop's form is defined by overlapping elliptical volumes that spiral in opposing directions, giving the tower an overall dynamic quality, and affording 360-degree views. The lower Skyloop interweaves several points of public access, including an observatory, destination restaurants and lush rooftop gardens. Above, hotel guests can enjoy secluded experiences: private cabanas, infinity-edge pools and shading palms. There will also be a cantilevered wellness terrace that is designed for yoga, arts and specialty events. Situated adjacent to the hotel tower, the podium serves as a bustling hotspot for business, entertainment and cultural exchange. At its core is a 15,000-seat state-of-the-art arena being helmed by global design firm Populous—responsible for some of the world's most recognisable entertainment venues, including the Sphere in Las Vegas and the O2 Arena in London. Specially designed to host the highest calibre of regional and international touring acts, concerts and large-scale live events, the venue will be optimised for unparalleled acoustics, sightlines and production flexibility. The venue will also be integrated with new and existing developments within the Marina Bay precinct for greater efficiency and pedestrian connectivity, providing direct access to Bayfront MRT station and linkways between Marina Bay and Gardens by the Bay. More than 220 guests attended the groundbreaking event tonight, which featured captivating performances by homegrown artist Jasmine Sokko and Canadian singer-songwriter and multi-instrumentalist Henry Lau. The lavish affair was accompanied by a curated culinary experience from Marina Bay Sands' signature restaurants, including a taste preview of upcoming Cantonese restaurant Jin Ting Wan. To commemorate the occasion, Marina Bay Sands was illuminated in a wash of golden hues—a stunning public spectacle that spanned the entire property from its three towers and the SkyPark Observation Deck to the Marina Bay Sands Expo & Convention Centre. In celebration of the milestone year of SG60, Marina Bay Sands also commissioned a cinematic tribute to the nation. Titled "Nothing Comes by Chance", the film by local director Kirsten Tan reflects on Singapore's commitment to shaping a bright future, underscored by resilience, ambition and constant reinvention that parallels Marina Bay Sands' growth and spirit. It features prominent Singaporean talents who have helped define its global presence across arts, culture, sports and entertainment, such as Tan Kheng Hua, Quah Zheng Wen, Pierre Png and Jasmine Sokko—offering a heartfelt ode to the nation. Shaping a Greener Horizon In line with Marina Bay Sands' global strategy Sands ECO360, sustainability will remain at the heart of the new building's architecture and operations. Different approaches towards designing shade for guest comfort and reduced energy consumption are being explored. This includes a self-shading façade system that utilises high-performance glazing and internal blinds to lower direct solar heat transfer and improve energy efficiency. Each suite will have its own private terrace and garden, while outdoor dining venues will be fitted with canopies to shield guests from the elements. Tree species native to the Southeast Asian region will also be planted where possible, paying tribute to the development's prime location. As construction works proceed, best practices will be adopted including the use of materials with reduced environmental impact such as low-carbon concrete and recycled steel to lower the project's upfront environmental footprint. A construction waste management plan has also been set in place, where on-site segregation and recycling will be implemented and at least 75 per cent of construction waste will be diverted to significantly reduce landfill disposal. Towards New Heights Since its inception, Marina Bay Sands has become an iconic symbol of Singapore, transforming the nation's tourism landscape as a leading leisure, business and entertainment destination in Asia. It hosted a record-breaking 2,200 events last year, drawing 1.2 million MICE delegates. In March this year, the property welcomed its 500 millionth visitor. With more than 12,000 Team Members directly employed by the integrated resort and 92 per cent of procurement spent on local businesses in 2024, it has also contributed to Singapore's economy through the creation of new jobs and support for homegrown small- and medium-sized enterprises (SMEs). These figures are set to rise in the coming years as Marina Bay Sands expands its operations in Singapore. "Over the years, Marina Bay Sands has been integral in strengthening Singapore's position as a major tourism powerhouse. By the time our new ultra-luxury development is complete, Las Vegas Sands will have invested more than US$15 billion since we started operations in Singapore in 2010. This speaks volumes of our confidence in this region, and the potential that we continue to see in Singapore," said Patrick Dumont, President and Chief Operating Officer of Las Vegas Sands. "We are privileged to have benefited over the past 15 years from factors that make Singapore great - excellent infrastructure, and a strong and supportive government with a forward-looking vision." Mr Dumont added: "We are proud of the transformative impact that Marina Bay Sands has had and are highly optimistic about building on this strong foundation. Our new development will raise the bar and redefine the ultra-luxury hospitality realm on a global scale, fuelling further growth of high-value tourism while our state-of-art arena will attract the world's most popular performers and usher in a new era of live entertainment in the region. We look forward to forging a new chapter together and continuing to contribute meaningfully to Singapore's future success." About Sands (NYSE: LVS) Sands is the leading global developer and operator of integrated resorts. The company's iconic properties drive valuable leisure and business tourism and deliver significant economic benefits, sustained job creation, financial opportunities for local businesses and community investment to help make its host regions ideal places to live, work and visit. Sands' portfolio of properties includes Marina Bay Sands® in Singapore and The Venetian® Macao, The Londoner Macao®, The Parisian Macao®, The Plaza Macao and Four Seasons Hotel Macao, and Sands® Macao in Macao SAR, China, through majority ownership in Sands China Ltd. Dedicated to being a leader in corporate responsibility, Sands is anchored by the core tenets of serving people, communities and the planet. The company's ESG leadership has led to inclusion on the Dow Jones Sustainability Indices for World and North America. To learn more, visit About Marina Bay Sands Pte Ltd Since its opening in 2010, Marina Bay Sands has stood as an architectural marvel and the crown jewel in Singapore's skyline. Home to the world's most spectacular rooftop infinity pool and approximately 1,850 rooms and suites, the integrated resort offers exceptional dining, shopping, meeting and entertainment choices, complete with a year-round calendar of signature events. Marina Bay Sands is dedicated to being a good corporate citizen to serve its people, communities and environment. It drives social impact through its community engagement programme, Sands Cares, and leads environmental stewardship through its global sustainability programme, Sands ECO360. For more information, please visit For factsheet and hi-res images (credit as indicated in the captions), please click [here] View original content to download multimedia: SOURCE Marina Bay Sands Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
